Compare Eli Lilly And Co (LLY) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M). The key difference: Eli Lilly And Co is far larger — about 1285.5× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| LLY | MSTU | |
|---|---|---|
Market Cap | $1.04T | $809.00M |
Volume | 3,064,878 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $432.00 |
52-Week Low | $799.57 | $14.60 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
MSTU trades at $38.33, down 2.84% with bearish technical signals dominating. The stock faces resistance at $40-$43 while finding support at $37-$35 levels. Recent corporate actions include a 10:1 reverse stock split effective August 2026 and a $0.29 dividend declaration. Technical indicators show mixed signals with moving averages bearish but oscillators neutral.
The outlook remains cautious given the bearish technical setup and lack of current fundamental data. Investment opportunity exists if the stock holds above $35 support, but risks include continued technical weakness and absence of recent financial metrics. The reverse split suggests management addressing potential price level concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
